DK1685125T3 - Pyrrolderivater der er nyttige til behandlingen af proliferative sygdomme - Google Patents

Pyrrolderivater der er nyttige til behandlingen af proliferative sygdomme

Info

Publication number: DK1685125T3
Authority: DK; Denmark
Prior art keywords: treatment; proliferative diseases; derivatives useful; pyrrole derivatives; pyrrole
Prior art date: 2003-11-19

Application number

DK04790859.5T

Other languages

English (en)

Inventor

Dirk Finsinger

Hans-Peter Buchstaller

Lars Burgdorf

Matthias Wiesner

Christiane Amendt

Matthias Grell

Christian Sirrenberg

Frank Zenke

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-19

Filing date

2004-10-26

Publication date

2012-07-23

2004-10-26 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2012-07-23 Application granted granted Critical

2012-07-23 Publication of DK1685125T3 publication Critical patent/DK1685125T3/da

Links

201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000002062 proliferating effect Effects 0.000 title 1
150000003233 pyrroles Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK04790859.5T 2003-11-19 2004-10-26 Pyrrolderivater der er nyttige til behandlingen af proliferative sygdomme DK1685125T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10354060A DE10354060A1 (de)	2003-11-19	2003-11-19	Pyrrolderivate
PCT/EP2004/012076 WO2005049603A1 (de)	2003-11-19	2004-10-26	Pyrrolderivate

Publications (1)

Publication Number	Publication Date
DK1685125T3 true DK1685125T3 (da)	2012-07-23

Family

ID=34530259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04790859.5T DK1685125T3 (da)	2003-11-19	2004-10-26	Pyrrolderivater der er nyttige til behandlingen af proliferative sygdomme

Country Status (19)

Country	Link
US (1)	US7598274B2 (da)
EP (1)	EP1685125B1 (da)
JP (1)	JP4805839B2 (da)
KR (1)	KR20060118492A (da)
CN (1)	CN1882571A (da)
AR (1)	AR046643A1 (da)
AU (1)	AU2004291255B2 (da)
BR (1)	BRPI0416690A (da)
CA (1)	CA2546334C (da)
CY (1)	CY1112947T1 (da)
DE (1)	DE10354060A1 (da)
DK (1)	DK1685125T3 (da)
ES (1)	ES2385329T3 (da)
MX (1)	MXPA06005478A (da)
PL (1)	PL1685125T3 (da)
PT (1)	PT1685125E (da)
SI (1)	SI1685125T1 (da)
WO (1)	WO2005049603A1 (da)
ZA (1)	ZA200604968B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en)	1999-01-13	2012-05-09	Bayer HealthCare LLC	w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DK1478358T3 (da)	2002-02-11	2013-10-07	Bayer Healthcare Llc	Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003068229A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl)	2003-07-23	2008-04-30	Bayer Healthcare Llc	Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
FR2881426B1 (fr) *	2005-02-03	2007-03-30	Aventis Pharma Sa	Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
FR2881742B1 (fr) *	2005-02-10	2007-09-07	Aventis Pharma Sa	Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
TWI444185B (zh) *	2007-04-09	2014-07-11	Daiichi Sankyo Co Ltd	吡咯衍生物之阻轉異構物
ES2458872T3 (es)	2009-04-30	2014-05-07	Novartis Ag	Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina
US8513289B2 (en)	2009-05-05	2013-08-20	Merck Sharp & Dohme Corp.	P38 kinase inhibiting agents
CN102146074B (zh) *	2011-01-26	2013-02-06	江苏先声药物研究有限公司	吡咯衍生物的制备方法及应用
JP6105594B2 (ja)	2011-09-30	2017-03-29	エンドゥファーマシューティカルズ，インコーポレイティド	癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
JP6130383B2 (ja)	2011-09-30	2017-05-17	エンドゥファーマシューティカルズ，インコーポレイティド	ピリジン誘導体
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
WO2017029684A1 (en) *	2015-08-17	2017-02-23	University Of Mysore	2,3,5 trisubstituted pyrrole derivatives as topoisomerase inhibitors and therapeutic uses thereof
EP3579872A1 (en)	2017-02-10	2019-12-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CA3086765A1 (en)	2017-12-28	2019-07-04	Tract Pharmaceuticals, Inc.	Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2021195360A1 (en) *	2020-03-27	2021-09-30	Landos Biopharma, Inc.	Plxdc2 ligands
TW202315628A (zh) *	2021-06-24	2023-04-16	南韓商Ｌｇ化學股份有限公司	作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747469A (en)	1991-03-06	1998-05-05	Board Of Regents, The University Of Texas System	Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en)	1999-02-25	1999-04-21	Pharmacia & Upjohn Spa	Antitumour synergistic composition
JP4783532B2 (ja) *	2000-02-05	2011-09-28	バーテックスファーマシューティカルズインコーポレイテッド	Ｅｒｋのインヒビターとして有用なピラゾール組成物
JP2004532234A (ja) *	2001-04-27	2004-10-21	バーテックス　ファーマシューティカルズ　インコーポレイテッド	トリアゾール由来キナーゼインヒビターおよびその使用
GB0121488D0 (en)	2001-09-05	2001-10-24	Smithkline Beecham Plc	Compounds
US20040138269A1 (en)	2002-10-11	2004-07-15	Sugen, Inc.	Substituted pyrroles as kinase inhibitors
PT1773768T (pt) *	2004-07-30	2018-11-30	Exelixis Inc	Derivados de pirrol como agentes farmacêuticos

2003
- 2003-11-19 DE DE10354060A patent/DE10354060A1/de not_active Withdrawn
2004
- 2004-10-26 PT PT04790859T patent/PT1685125E/pt unknown
- 2004-10-26 BR BRPI0416690-6A patent/BRPI0416690A/pt not_active Application Discontinuation
- 2004-10-26 ES ES04790859T patent/ES2385329T3/es not_active Expired - Lifetime
- 2004-10-26 DK DK04790859.5T patent/DK1685125T3/da active
- 2004-10-26 CA CA2546334A patent/CA2546334C/en not_active Expired - Fee Related
- 2004-10-26 KR KR1020067009552A patent/KR20060118492A/ko not_active Withdrawn
- 2004-10-26 WO PCT/EP2004/012076 patent/WO2005049603A1/de not_active Ceased
- 2004-10-26 EP EP04790859A patent/EP1685125B1/de not_active Expired - Lifetime
- 2004-10-26 CN CNA2004800343453A patent/CN1882571A/zh active Pending
- 2004-10-26 JP JP2006540216A patent/JP4805839B2/ja not_active Expired - Fee Related
- 2004-10-26 US US10/579,825 patent/US7598274B2/en not_active Expired - Fee Related
- 2004-10-26 PL PL04790859T patent/PL1685125T3/pl unknown
- 2004-10-26 MX MXPA06005478A patent/MXPA06005478A/es unknown
- 2004-10-26 SI SI200431902T patent/SI1685125T1/sl unknown
- 2004-10-26 AU AU2004291255A patent/AU2004291255B2/en not_active Ceased
- 2004-11-19 AR ARP040104272A patent/AR046643A1/es unknown
2006
- 2006-06-15 ZA ZA200604968A patent/ZA200604968B/en unknown
2012
- 2012-07-31 CY CY20121100678T patent/CY1112947T1/el unknown

Also Published As

Publication number	Publication date
EP1685125B1 (de)	2012-06-06
SI1685125T1 (sl)	2012-08-31
CY1112947T1 (el)	2016-04-13
CA2546334A1 (en)	2005-06-02
ES2385329T3 (es)	2012-07-23
CA2546334C (en)	2012-06-19
KR20060118492A (ko)	2006-11-23
AU2004291255A1 (en)	2005-06-02
ZA200604968B (en)	2007-10-31
DE10354060A1 (de)	2005-06-02
AR046643A1 (es)	2005-12-14
US20070149594A1 (en)	2007-06-28
PL1685125T3 (pl)	2012-10-31
PT1685125E (pt)	2012-09-12
AU2004291255B2 (en)	2011-02-03
MXPA06005478A (es)	2006-08-11
WO2005049603A1 (de)	2005-06-02
CN1882571A (zh)	2006-12-20
JP2007511553A (ja)	2007-05-10
JP4805839B2 (ja)	2011-11-02
BRPI0416690A (pt)	2007-01-30
EP1685125A1 (de)	2006-08-02
US7598274B2 (en)	2009-10-06

Publication	Publication Date	Title
DK1633726T3 (da)	2011-03-28	Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
DK1701941T3 (da)	2012-08-13	Forbindelser til behandling af sygdomme med celleproliferation
DK1656347T3 (da)	2011-01-10	Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1803718T3 (da)	2008-10-27	4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
EP1829877A4 (en)	2009-10-14	BICYCLIC PYRROL DERIVATIVES
DK3342411T3 (da)	2019-09-02	Rapamycinderivat til behandling af pancreascancer
IS8398A (is)	2006-04-05	Lyfjasamsetningar til að meðhöndla æxli
DK1828164T3 (da)	2008-12-08	Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da)	2013-09-30	Fremgangsmåde til fremstilling af dihydropteridion
DK1708992T3 (da)	2007-11-05	Sulfonamidderivater til behandling af sygdomme
DK1474416T3 (da)	2008-01-14	Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1928438T3 (da)	2013-04-22	Anvendelse af ibudilast til behandling af stofafhængighed
DE602005023172D1 (de)	2010-10-07	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
PL1685125T3 (pl)	2012-10-31	Pochodne pirrolowe użyteczne do leczenia chorób proliferacyjnych
DK1499730T3 (da)	2014-01-13	Immunokonjugater til behandling af tumorer
DK1708991T3 (da)	2008-01-14	Sulfonamid derivater til behandling af sygdomme
IS8125A (is)	2005-11-11	Kínasólínafleiður til að meðhöndla krabbamein
DK1948615T3 (da)	2012-02-06	Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK1667967T3 (da)	2012-10-08	Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
IS6917A (is)	2003-08-18	Epóþílon afleiður til meðhöndlunar erfiðra æxla
DK1694122T3 (da)	2007-12-03	N-arylhydrazonderivater til fröbehandling
DK1487828T3 (da)	2009-02-02	Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK2189162T3 (da)	2014-02-03	Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1589973T4 (da)	2013-04-08	Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1756049T3 (da)	2008-02-25	Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater